Dellagi Lamia, Ben Azouz Olfa, Johnson Ines, Kebir Oussama, Amado Isabelle, Tabbane Karim
Unité de recherche UR 02/04 sur les processus cognitifs dans la pathologie psychiatrique, hôpital Razi, Tunis.
Tunis Med. 2009 Oct;87(10):660-3.
Despite progress in chemo-therapeutics, schizophrenia remains a chronic disease with occurrence of residual symptoms and drug resistance in 60% of the cases. Besides, cognitive impairment is frequent and highly correlated to social dysfunction seen in patients with schizophrenia. Several cognitive remediation programs have been elaborated. REHACOM is one of such programs. Aim of the study is to evaluate through a case control the efficiency of REHACOM towards cognitive functions.
This program has been administered to a patient suffering from undifferentiated schizophrenia which was ameliorated after drug therapy considering positive symptoms but still was complaining from cognitive deficits causing social withdrawal.
After following the remediation program, the patient was ameliorated considering its negative symptoms as attested by an amelioration of the PANSS negative score and considering its cognitive performances on memory, attention and executive functions. We have also noticed an improvement in his self-esteem and his quality of life.
This first trial of a cognitive remediation program among our patients suffering from schizophrenia using REHACOM was encouraging. Enlarging its use and designing controlled studies will be the next step of our study.
尽管化疗取得了进展，但精神分裂症仍然是一种慢性病，60%的病例会出现残留症状和耐药性。此外，认知障碍很常见，并且与精神分裂症患者的社会功能障碍高度相关。已经制定了几种认知康复计划。REHACOM就是其中之一。本研究的目的是通过病例对照评估REHACOM对认知功能的有效性。
该计划已应用于一名患有未分化型精神分裂症的患者，该患者在药物治疗后阳性症状有所改善，但仍抱怨认知缺陷导致社交退缩。
在遵循康复计划后，患者的阴性症状得到改善，PANSS阴性评分有所改善，其在记忆、注意力和执行功能方面的认知表现也得到改善。我们还注意到他的自尊和生活质量有所提高。
我们使用REHACOM对精神分裂症患者进行的首次认知康复计划试验令人鼓舞。扩大其使用范围并设计对照研究将是我们研究的下一步。
